Takeda Pharmaceutical Co. Ltd. (TKPYY) Snaps Up InViragen for Up to $250 Million
5/8/2013 7:20:18 AM
More...
|
InViragen Advances DENVax into Second Stage of Ongoing Phase 2 Clinical Study
2/27/2013 11:07:23 AM
More...
|
VABIOTECH Licenses Cell-Based Japanese Encephalitis Technology From InViragen
1/3/2013 11:23:22 AM
More...
|
InViragen and the International Vaccine Institute Expand Partnership
11/8/2012 10:20:09 AM
More...
|
InViragen to Participate in Biotechnology Industry Organization (BIO) Ventures for Global Health Press Briefing June 18
6/14/2012 10:23:07 AM
More...
|
InViragen Hand, Foot and Mouth Disease Vaccine Generates Immune Responses in 100% of Study Participants
3/12/2012 8:03:29 AM
More...
|
InViragen Enlists Advanced BioScience Laboratories, Inc. for Manufacture of Master Virus Seed Stock for Plague Vaccine Development
2/8/2012 7:24:05 AM
More...
|
InViragen Presents Safety and Immune Response Data from a Phase 1 Study of its Two-Dose Dengue Vaccine, DENVax
12/7/2011 7:14:20 AM
More...
|
InViragen Initiates a Phase 2 Clinical Study of DENVax, a Recombinant, Tetravalent Dengue Vaccine
11/28/2011 10:47:47 AM
More...
|
InViragen and University of Texas Medical School Receive Funding for Development of a Novel Recombinant Chikungunya Virus Vaccine
8/16/2011 8:53:51 AM
More...
|
|